Less bleeding seen with rivaroxaban in large lung clot study

03/27/2012 | Reuters

The anticoagulant rivaroxaban is safer than and works as well as standard dual therapy for blood clots of the lung, according to a 4,833-patient study presented at a cardiology meeting. A lower percentage of patients taking rivaroxaban experienced major and minor bleeding compared with those who took the combination therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC